Skip to main
RXST
RXST logo

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 0%
Hold 67%
Sell 22%
Strong Sell 0%

Bulls say

RxSight Inc is showing promising financial trends, with a reported operating expense of $36.4 million, reflecting a modest year-over-year increase of $2.0 million while revenues exceeded consensus expectations in the third quarter of 2025. The company's management has raised its gross margin guidance for 2025 to a range of 76-77%, indicating a focus on improved profitability, alongside a commitment to strategic growth in LDD placements and higher utilization rates. Furthermore, potential upside drivers such as accelerating LDD installed base growth, increased volumes of light adjustable lenses, and enhanced margins reinforce a strong outlook for sustained double-digit revenue growth.

Bears say

RxSight Inc has experienced a decline in key utilization metrics, with monthly utilization for light adjustable lenses dropping to 8.0 per LDD in Q3 2025, down from 8.7 in Q2 2025 and 10.1 in Q3 2024. Revenue for the company fell to $30.3 million, representing a 14% year-over-year decrease, while LDD placements sharply declined by 68% year-over-year and 38% quarter-over-quarter, falling short of investor expectations. Additionally, risks to the company's outlook include limited product adoption, disappointing commercial performance, heightened competition in the intraocular lens market, and the potential need for dilutive financing.

RxSight (RXST) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 9 analysts, RxSight (RXST) has a Hold consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.